384 related articles for article (PubMed ID: 30620624)
21. Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells.
Hosonaga M; Arima Y; Sugihara E; Kohno N; Saya H
Cancer Sci; 2014 Jul; 105(7):779-87. PubMed ID: 24754246
[TBL] [Abstract][Full Text] [Related]
22. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
[TBL] [Abstract][Full Text] [Related]
23. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Sanz-Moreno A; Palomeras S; Pedersen K; Morancho B; Pascual T; Galván P; Benítez S; Gomez-Miragaya J; Ciscar M; Jimenez M; Pernas S; Petit A; Soler-Monsó MT; Viñas G; Alsaleem M; Rakha EA; Green AR; Santamaria PG; Mulder C; Lemeer S; Arribas J; Prat A; Puig T; Gonzalez-Suarez E
Breast Cancer Res; 2021 Mar; 23(1):42. PubMed ID: 33785053
[TBL] [Abstract][Full Text] [Related]
24. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
[TBL] [Abstract][Full Text] [Related]
25. Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.
Chung WP; Huang WL; Liao WA; Huang WL; Liu YY; Su WC
Cancer Med; 2021 Apr; 10(7):2370-2379. PubMed ID: 33665980
[TBL] [Abstract][Full Text] [Related]
26. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
27. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
28. Disulfiram targets cancer stem-like properties and the HER2/Akt signaling pathway in HER2-positive breast cancer.
Kim JY; Cho Y; Oh E; Lee N; An H; Sung D; Cho TM; Seo JH
Cancer Lett; 2016 Aug; 379(1):39-48. PubMed ID: 27238567
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.
Li W; Zhai L; Wang H; Liu C; Zhang J; Chen W; Wei Q
Oncotarget; 2016 May; 7(19):27778-86. PubMed ID: 27034004
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
31. Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options.
Burnett JP; Korkaya H; Ouzounova MD; Jiang H; Conley SJ; Newman BW; Sun L; Connarn JN; Chen CS; Zhang N; Wicha MS; Sun D
Sci Rep; 2015 Nov; 5():15821. PubMed ID: 26522776
[TBL] [Abstract][Full Text] [Related]
32. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
33. A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer.
Park JM; Kim YJ; Park S; Park M; Farrand L; Nguyen CT; Ann J; Nam G; Park HJ; Lee J; Kim JY; Seo JH
Mol Cancer; 2020 Nov; 19(1):161. PubMed ID: 33218356
[TBL] [Abstract][Full Text] [Related]
34. Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers.
Baldassarre T; Truesdell P; Craig AW
Breast Cancer Res; 2017 Oct; 19(1):110. PubMed ID: 28974266
[TBL] [Abstract][Full Text] [Related]
35. β2-AR signaling controls trastuzumab resistance-dependent pathway.
Liu D; Yang Z; Wang T; Yang Z; Chen H; Hu Y; Hu C; Guo L; Deng Q; Liu Y; Yu M; Shi M; Du N; Guo N
Oncogene; 2016 Jan; 35(1):47-58. PubMed ID: 25798840
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.
Mukohara T
Cancer Sci; 2011 Jan; 102(1):1-8. PubMed ID: 20825420
[TBL] [Abstract][Full Text] [Related]
37. HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in an NFκB-dependent way.
Wang W; Gao Y; Hai J; Yang J; Duan S
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30314995
[TBL] [Abstract][Full Text] [Related]
38. Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models.
Yang L; Bhattacharya A; Peterson D; Li Y; Liu X; Marangoni E; Robila V; Zhang Y
Drug Resist Updat; 2024 May; 74():101078. PubMed ID: 38503142
[TBL] [Abstract][Full Text] [Related]
39. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits.
Chung SS; Giehl N; Wu Y; Vadgama JV
Int J Oncol; 2014 Feb; 44(2):403-11. PubMed ID: 24297508
[TBL] [Abstract][Full Text] [Related]
40. Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer.
Alexander PB; Chen R; Gong C; Yuan L; Jasper JS; Ding Y; Markowitz GJ; Yang P; Xu X; McDonnell DP; Song E; Wang XF
J Biol Chem; 2017 Jan; 292(2):748-759. PubMed ID: 27903634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
